Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Apatinib or Chemotherapy for Neoadjuvant NSCLC
NCT04379739Phase 2Active, not recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Started Jul 2020; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04379739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04379739.